Trial reportAnnals of the rheumatic diseases2010
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
Trial report in Annals of the rheumatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- The efficacy of systemic glucocorticosteroids for pain in rheumatoid arthritis: a systematic literature review and meta-analysis.Rheumatology (Oxford, England) · 2021Pooled it
- [Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2012Pooled it
- Circadian Modulation of the Antioxidant Effect of Grape Consumption: A Randomized Controlled Trial.International journal of environmental research and public health · 2023Trial
- Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.Scandinavian journal of rheumatology · 2015Trial
- Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).Annals of the rheumatic diseases · 2013Trial
- Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework.Digestive diseases and sciences · 2026Review
- Translational applications of circadian research: connecting chronobiology to medicine.Npj biological timing and sleep · 2026Review
- Programmable chronogenetic gene circuits for self-regulated circadian delivery of biologic drugs.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Biological Clock Perspective in Rheumatoid Arthritis.Inflammation · 2025Review
- Article
- Cortisol Monitoring Devices toward Implementation for Clinically Relevant Biosensing In Vivo.Molecules (Basel, Switzerland) · 2023Review
- Timing of diuretic administration effects on urine volume in hospitalized patients.Frontiers in physiology · 2023Article
- Chronobiology and Chronotherapy in Inflammatory Joint Diseases.Pharmaceutics · 2021Review
- Circadian Variation in Efficacy of Medications.Clinical pharmacology and therapeutics · 2021Review
- Circadian rhythms in innate immunity and stress responses.Immunology · 2020Review
- Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Views on glucocorticoid therapy in rheumatology: the age of convergence.Nature reviews. Rheumatology · 2020Review
- Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery.Journal of pharmacopuncture · 2019Review
- Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study.Rheumatology and therapy · 2017Article
- Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.International journal of molecular sciences · 2017Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis 9-month open-label extension of the Circadian Administration of Prednisone in Rheumatoid Arthritis Study (CAPRA 1) investigated the long-term safety and efficacy of prednisone chronotherapy with a novel modified-release (MR) prednisone for up to 12 months.
methodsOf 288 patients with rheumatoid arthritis originally randomised to MR or immediate-release (IR) prednisone, 249 continued with prednisone chronotherapy (2-10 mg/day) in the 9-month open-label extension. Duration of morning stiffness of the joints (MS), disease activity scores (DAS28), American College of Rheumatology (ACR20) responses and plasma levels of interleukin 6 (IL-6) were assessed. Safety was analysed from adverse event reports and laboratory investigations.
resultsDuring the 3-month double-blind phase, patients in the MR group achieved a reduction in MS of 33.1% while no change was observed in the IR group. After 6 months of treatment, MS was reduced in the IR/MR group by 54% and in the MR/MR group by 56%. MS reduction after 12 months was 45% (IR/MR group) and 55% (MR/MR group). Plasma levels of IL-6 declined on MR treatment. DAS28 was reduced from 5.8 to 4.8 (MR/MR group) and 4.9 (IR/MR group), respectively. 37% of the 219 patients who completed the 12-month study achieved improvement according to the ACR20 criteria. Adverse events did not differ from the known profile of low-dose prednisone.
conclusionsPrednisone chronotherapy with the MR tablet was safe and well tolerated and provided a sustained improvement which resulted in a better benefit to risk ratio of low-dose glucocorticoid treatment for at least 12 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.